Related references
Note: Only part of the references are listed.Treat-to-Target Approach in Rheumatoid Arthritis: A Quality Improvement Trial
Sonali P. Desai et al.
ARTHRITIS CARE & RESEARCH (2021)
Treat-to-Target From the Patient Perspective Is Bowling for a Perfect Strike
Casper G. Schoemaker et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Immunogenicity of biologic agents in rheumatology
Vibeke Strand et al.
NATURE REVIEWS RHEUMATOLOGY (2021)
Why remission is not enough: underlying disease mechanisms in RA that prevent cure
Georg Schett et al.
NATURE REVIEWS RHEUMATOLOGY (2021)
Patient and Rheumatologist Perspectives on Tapering DMARDs in Rheumatoid Arthritis: A Qualitative Study (Apr, keab330, 2021)
Glen S. Hazlewood et al.
RHEUMATOLOGY (2021)
Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: a systematic review
Ahmad A. Sherbini et al.
RHEUMATOLOGY (2021)
Patient-reported outcomes in RA care improve patient communication, decision-making, satisfaction and confidence: qualitative results
Susan J. Bartlett et al.
RHEUMATOLOGY (2020)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
New galaxies in the universe of shared decision-making and rheumatoid arthritis
Jennifer L. Barton et al.
CURRENT OPINION IN RHEUMATOLOGY (2020)
Correlation of patient preferences to treatment outcomes in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors in Greece
Prodromos Sidiropoulos et al.
CLINICAL RHEUMATOLOGY (2020)
Three-year cost-effectiveness analysis of the DRESS study: protocolised tapering is key
Nathan den Broeder et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Methotrexate mechanism in treatment of rheumatoid arthritis
Benjamin Friedman et al.
JOINT BONE SPINE (2019)
Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study
Elise van Mulligen et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis
Giulio Cavalli et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2019)
The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis
Yoshiya Tanaka et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Rheumatoid arthritis
Josef S. Smolen et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
DMARD de-escalation-let the patient guide you
Yoshiya Tanaka
NATURE REVIEWS RHEUMATOLOGY (2017)
Dosing down with biologic therapies: a systematic review and clinicians' perspective
Christopher J. Edwards et al.
RHEUMATOLOGY (2017)
Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial
Chantal A. M. Bouman et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial
Tatsuya Atsumi et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions
Georg Schett et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis
Yoshiya Tanaka
RHEUMATOLOGY (2016)
Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
Yoshiya Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Longterm Effect of Delaying Combination Therapy with Tumor Necrosis Factor Inhibitor in Patients with Aggressive Early Rheumatoid Arthritis: 10-year Efficacy and Safety of Adalimumab from the Randomized Controlled PREMIER Trial with Open-label Extension
Edward C. Keystone et al.
JOURNAL OF RHEUMATOLOGY (2014)
Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal?
Yoshiya Tanaka
ANNALS OF THE RHEUMATIC DISEASES (2013)
Shared Decision Making: A Model for Clinical Practice
Glyn Elwyn et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2012)
Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
Y. Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Share Paper
